China’s NDRC Formulates Policies For Drug Price Reduction
This article was originally published in PharmAsia News
Executive Summary
China's National Development and Reform Commission has put another round of drug price reduction on its agenda for discussion. This time it will also look at single-pricing for off-patent drugs, "quality price for quality drugs" and healthcare institution drug price increases. Participating experts disclose that a slew of policies to lower drug prices will be released late 2008, which will mainly be directed at pharmaceutical MNCs to reduce their overly-high drug pricing. Currently, healthcare institutions may raise the cost price of drugs by 15 percent as income. NDRC will identify a mandatory standard such that institutions can only increase a fixed amount once the drug price exceeds the standard, a measure to prevent indiscriminate selection of high-priced drugs for greater profits. (Click here for more - Chinese Language)
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.